Abstract
The role of C-reactive protein (CRP) as a mediator of atherogenesis/atherothrombosis, and, thus, as a potential therapeutic target to fight cardiovascular disease (CVD) is still elusive. In this review, we focus on CRP as a potential mediator of CVD analysing CRP signalling data derived from relevant in vitro and animal models related to inflammation, endothelial dysfunction, primary, and secondary haemostasis, all representing pathophysiological events of recognised importance in CVD. If in vitro studies appear to make a strong case of CRP as a proatherogenic/ prothrombotic molecule through nuclear factor-kappa B (NFκB) and peroxisome proliferator-activated receptor gamma (PPARγ) pathways, animal studies as well as human mendelian randomisation studies do not corroborate those in vitro observations. Several explanations might account for this discrepancy, but CRP contamination with biologically active compounds, such as bacterial compounds or sodium azide, remains an important potential confounding factor. Therefore, knowing whether CRP is a mediator of atherogenesis and CVD or just an innocent bystander reflecting the degree of unspecific systemic inflammation will most likely remain debated until the completion of clinical randomised controlled trials using selective inhibitors of CRP. This in turn prompts questions about whether CRPreducing agents will prevent atherogenesis-related complication in humans.
Keywords: C-reactive protein, atherosclerosis, signaling pathways, cardiovascular disease, inflammation
Current Signal Transduction Therapy
Title:CRP Pro-inflammatory Signalling in Atherosclerosis: Myth or Reality?
Volume: 7 Issue: 2
Author(s): Sabrina Pagano, Pierre-Frederic Keller and Nicolas Vuilleumier
Affiliation:
Keywords: C-reactive protein, atherosclerosis, signaling pathways, cardiovascular disease, inflammation
Abstract: The role of C-reactive protein (CRP) as a mediator of atherogenesis/atherothrombosis, and, thus, as a potential therapeutic target to fight cardiovascular disease (CVD) is still elusive. In this review, we focus on CRP as a potential mediator of CVD analysing CRP signalling data derived from relevant in vitro and animal models related to inflammation, endothelial dysfunction, primary, and secondary haemostasis, all representing pathophysiological events of recognised importance in CVD. If in vitro studies appear to make a strong case of CRP as a proatherogenic/ prothrombotic molecule through nuclear factor-kappa B (NFκB) and peroxisome proliferator-activated receptor gamma (PPARγ) pathways, animal studies as well as human mendelian randomisation studies do not corroborate those in vitro observations. Several explanations might account for this discrepancy, but CRP contamination with biologically active compounds, such as bacterial compounds or sodium azide, remains an important potential confounding factor. Therefore, knowing whether CRP is a mediator of atherogenesis and CVD or just an innocent bystander reflecting the degree of unspecific systemic inflammation will most likely remain debated until the completion of clinical randomised controlled trials using selective inhibitors of CRP. This in turn prompts questions about whether CRPreducing agents will prevent atherogenesis-related complication in humans.
Export Options
About this article
Cite this article as:
Pagano Sabrina, Keller Pierre-Frederic and Vuilleumier Nicolas, CRP Pro-inflammatory Signalling in Atherosclerosis: Myth or Reality?, Current Signal Transduction Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157436212800376681
DOI https://dx.doi.org/10.2174/157436212800376681 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Current Vascular Pharmacology Coronary Magnetic Resonance Imaging
Current Pharmaceutical Design Cardiac Amyloid - A Hidden Contributor to Cardiac Dysfunction Following Cardiac Surgery: Case Report and Literature Review
Current Cardiology Reviews Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?
Recent Patents on Cardiovascular Drug Discovery The Effect of Borage (Echium amoenum) on the Mouse Heart and Hematology Parameters
Cardiovascular & Hematological Disorders-Drug Targets Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine
Current Pharmaceutical Design BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design <i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs Preface [Hot Topic: Recent Progress in Cardiovascular Gene Therapy;Emerging to Real Drug? (Guest Editor: Ryuichi Morishita)]
Current Gene Therapy Pulmonary Arterial Hypertension in Connective Tissue Diseases
Current Respiratory Medicine Reviews Pathogenesis of Neointima Formation Following Vascular Injury
Cardiovascular & Hematological Disorders-Drug Targets Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Extracellular Matrix Scaffolds for Tissue Engineering and Regenerative Medicine
Current Stem Cell Research & Therapy Systems Biology and Biomechanical Model of Heart Failure
Current Cardiology Reviews Diagnostic Value of Postprandial Triglyceride Testing in Healthy Subjects:A Meta-Analysis
Current Vascular Pharmacology Reduction of Myocardial Ischemia-Reperfusion Injury with Pre- and Postconditioning: Molecular Mechanisms and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets Pulmonary Arterial Hypertension: Need to Treat
Inflammation & Allergy - Drug Targets (Discontinued) Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design Olive Oil and Apoptosis of Cancer Cells
Current Nutrition & Food Science